Jeffrey Moses and C. Michael Gibson discuss a randomized trial of cerebral embolic protection during TAVR.

Salim Yusuf and C. Michael Gibson discuss aspirin alone and in combination with a polypill for CVD primary prevention.

Philipp Lurz and C. Michael Gibson discuss a randomized trial of ASD closure after TMVr.

Roxana Mehran and C. Michael Gibson discuss 3-month and 1-month DAPT after everolimus-eluting stents in high-bleeding-risk patients.

Steven Steinhubl and C. Michael Gibson discuss 3-year outcomes in a nationwide, randomized, pragmatic clinical trial of A-fib screening.

Damien Collison and C. Michael Gibson discuss a randomized trial of physiology-guided PCI optimization.

A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.

Dean Kereiakes and C. MIchael Gibson discuss a randomized trial of a novel, ultra-low-profile fixed-wire DES.

Robert Harrington and C. Michael Gibson discuss the registry's design, implementation, and initial results.

Ehrin Armstrong and C. Michael Gibson discuss a randomized, dose-escalation trial of temsirolimus adventitial delivery below the knee.